CPHI Milan spotlights India pharma’s missing-middle export gap
In short
Indian pharma and chemical firms at CPHI Milan say there is a real chance to win more business as companies look beyond China. But they also say many smaller firms cannot grow fast enough because of weak financing, small scale and technology limits.
That could slow export gains for India’s MSMEs. The reporting does not name specific companies or say what policy help, if any, is coming.
What the reporting says
Indian pharma and chemical companies at CPHI Milan are highlighting a China+1 opportunity, while saying a missing middle in the MSME ecosystem is holding back export growth. The publisher summary cites financing gaps, limited scale and technology constraints as the main blockers. The reporting does not identify specific companies, export targets or policy responses.
Why it matters
Indian pharma and chemical companies at CPHI Milan are pointing to a China+1 export opportunity, but say a missing middle in the MSME ecosystem is limiting growth. The cited problems are financing gaps, limited scale and technology constraints. The story suggests a structural bottleneck for exporters, but it does not name firms, quantify lost exports, or describe any official action.